Key facts
- This page summarizes Douglas J. Williamson's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Feb 2023, 17:45.
Douglas J. Williamson - 10 Feb 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- Executive VP, Research & Dev
- Issuer ticker
- ACAD
- Reported as of
- 10 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2023, 17:45:02 UTC
- Prior SEC filing
- 13 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Austin D. Kim, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas J. Williamson filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 13 Feb 2023.
Change
- Previous filing in this sequence was filed on 13 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Non-Qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +237,296
- Change %
- Price
- $0.000000
- Shares after
- 237,296
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 237,296
- Exercise price
- $18.97
- Footnotes
- F1
ACAD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +50,655
- Change %
- Price
- $0.000000
- Shares after
- 50,655
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,655
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
25% of the shares subject to the stock option vest on the first anniversary of February 10, 2023, with the balance vesting in 36 equal monthly installments thereafter, such that the shares subject to the option will be fully vested on the fourth anniversary of such date.
Footnote F2
Each restricted stock unit is subject to the 2023 Inducement Plan and represents a contingent right to receive one share of Acadia common stock.
Footnote F3
50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date.